Sherwin-Williams retreat creates excellent entry point, says Longbow After Sherwin-Williams announced the termination of its exclusive agreement with the sellers of Comex as it failed to obtain approval from Mexican regulators for the deal, Longbow believes that Sherwin-Williams' outlook "has rarely looked brighter." The firm thinks the stock's multiple can rise, and it reiterates a $215 price target and Buy rating on the shares.
Sherwin-Williams upgraded to Neutral from Sell at UBS UBS analyst John Roberts upgraded Sherwin-Williams to Neutral citing the relative underperformance of shares. The stock is high quality and "difficult to be bearish on," Roberts tells investors in a research note. He raised his price target for shares to $284 from $278.